<DOC>
	<DOC>NCT00635557</DOC>
	<brief_summary>This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.</brief_summary>
	<brief_title>Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically proven WHO Grade IV glioblastoma multiforme at time of diagnosis or relapse Prior treatment with radiotherapy and temozolomide Evidence of measurable recurrent or residual primary tumor by contrastenhanced MRI Be a minimum of 4 weeks since prior surgical resection, major surgical procedure, radiation therapy or cytotoxic chemotherapy (6 weeks since prior BCNU or CCNU) Have a Performance Scale of Karnofsky &gt; 60%, ECOG &lt; 2 or WHO &lt; 2 If steroids are needed, be on a stable or decreasing dose of steroids for at least 1 week Hypersensitivity to Cremophor EL Have evidence of current/active intratumor hemorrhage by MRI Have greater than second relapse Have had prior treatment with platinumbased chemotherapy Have cardiovascular disease Have cerebrovascular disease Have uncontrolled hypertension Have a cardiac ejection fraction &lt; 50% Have TroponinI elevated above the normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Recurrent</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Multiforme</keyword>
</DOC>